ARTICLE | Company News
BZL Biologics L.L.C., Millennium deal
April 16, 2001 7:00 AM UTC
MLNM will use BZL's humanized J591 antibody to develop and commercialize both immunotoxin and radiolabeled antibodies targeting Prostate Specific Membrane Antigen ( PSMA). MLNM and BZL will jointly de...